Literature DB >> 6982736

Phorbol-ester-mediated induction and augmentation of mitogenesis and interleukin-2 production in human T-cell lymphoproliferative disease.

F A Vyth-Dreese, H J van der Reijden, J E de Vries.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6982736

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Analysis of helper activity on pokeweed mitogen- and interleukin 2-driven immunoglobulin synthesis by neoplastic T4+ cells.

Authors:  F Miedema; J W van Oostveen; F G Terpstra; A W van den Wall Bake; R Willemze; E A Rauws; R Bieger; M B van 't Veer; D Catovsky; C J Melief
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

2.  Phenotype study with monoclonal antibodies of T lymphocyte colonies in normal individuals and in patients with chronic OKT8+ lymphocytic leukaemia.

Authors:  C Andre; J P Farcet; N Oudhriri; M F Gourdin; J Bouguet; F Reyes
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

3.  Immunodeficiency with defective T-cell response to interleukin 1.

Authors:  E T Chu; L J Rosenwasser; C A Dinarello; F S Rosen; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

4.  Effects of 12-o-tetradecanoyl-phorbol-13-acetate (TPA) on the colony growth of human T lymphocytes.

Authors:  R Foa; P Lusso; M T Fierro; M C Giubellino; M L Ferrando; L Pegoraro
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

5.  Regulatory effect of interleukin-4 (IL-4) on the expression and function of lymphocyte adhesion receptors involved in IL-2-induced cell aggregation.

Authors:  F A Vyth-Dreese; Y Van Kooyk; T A Dellemijn; C J Melief; C G Figdor
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

6.  Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.

Authors:  L T Vlasveld; A Hekman; F A Vyth-Dreese; C J Melief; J J Sein; A C Voordouw; T A Dellemijn; E M Rankin
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

7.  A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.

Authors:  L T Vlasveld; A Hekman; F A Vyth-Dreese; E M Rankin; J G Scharenberg; A C Voordouw; J J Sein; T A Dellemijn; S Rodenhuis; C J Melief
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.